ONC
BeOne Medicines Ltd.
$308.96
-0.50 (-0.16%)
At close · Jul 7
Market Cap
$446.53B
Shares
1,445,262,342
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$5.34B
+40.2%
FY2025
Net Income
$286.93M
+144.5%
FY2025
Gross Margin
87.49%
+3.1pp
FY2025
Operating Margin
8.37%
+23.3pp
FY2025
Diluted EPS
$0.19
+140.4%
FY2025
Operating Cash Flow
$1.13B
+901.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $6.3B – $6.5B | $5.74B | $5.34B | $3.81B | $2.46B | $1.42B | $1.18B | $308.87M | $428.21M | $198.22M | $238.39M | $1.07M | $8.82M | $13.04M | |
| — | $72.31M | — | — | $74.01M | $52.48M | -$15.76M | $2M | $9.13M | $13.95M | -$4.11M | $383K | $559K | -$3.51M | |
| — | $347.61M | — | — | — | $286.48M | $164.91M | $70.66M | $71.19M | $28.71M | $4.97M | $0 | — | — | |
| — | $5.07B | $4.67B | $3.22B | $2.08B | $1.13B | $1.01B | — | — | — | — | — | — | — | |
| — | — | 87.49% | 84.41% | 84.55% | 79.77% | 85.98% | — | — | — | — | — | — | — | |
| — | $2.21B | $2.15B | $1.95B | $1.78B | $1.64B | $1.46B | $1.29B | $927.34M | $679.01M | $269.02M | $98.03M | $58.25M | $21.86M | |
| — | $32.61M | — | — | — | — | — | — | — | — | — | $20.1M | $7.31M | $6.93M | |
| — | $2.18B | $2.08B | $1.83B | $1.51B | $1.28B | $990.12M | $600.18M | $388.25M | $195.39M | $62.6M | $20.1M | $7.31M | — | |
| — | $10.64M | $10.07M | $4.82M | $7.24M | $3.98M | $1.72M | $846K | $1.33M | $894K | $250K | $0 | $0 | — | |
| — | — | $141.69M | $171.76M | $87.68M | $66.28M | $46.46M | $31.79M | $18.62M | $10.39M | $4.76M | $1.91M | $1.55M | — | |
| — | $4.38B | $4.23B | $3.78B | $3.29B | $2.92B | $2.45B | $1.97B | $1.39B | $903.99M | $336.84M | $118.13M | $65.56M | $28.79M | |
| — | $685.94M | $447.14M | -$568.2M | -$1.21B | -$1.79B | -$1.44B | -$1.66B | -$959.89M | -$705.77M | -$98.46M | -$117.06M | -$56.75M | -$15.76M | |
| — | — | 8.37% | -14.91% | -49.12% | -126.4% | -122.31% | -536.69% | -224.16% | -356.05% | -41.3% | -10940.19% | -643.66% | -120.88% | |
| — | — | $588.82M | -$396.44M | -$1.12B | -$1.72B | -$1.39B | -$1.63B | -$941.27M | -$695.38M | -$93.7M | -$115.15M | -$55.2M | — | |
| — | — | $58.23M | $21.81M | $4.36M | — | — | — | — | — | — | — | — | — | |
| — | — | $70.51M | $69.64M | $78.37M | — | — | — | — | — | — | — | — | — | |
| — | -$31.97M | -$42.55M | -$12.64M | $307.89M | -$223.85M | $15.9M | $37.49M | $7.17M | $1.99M | $11.5M | -$972K | $1.22M | $600K | |
| — | — | — | — | -$16.22M | -$22M | $7.63M | $11.83M | $0 | $0 | — | — | — | — | |
| — | — | -$596K | -$17.18M | -$8.69M | — | — | — | — | — | — | — | — | — | |
| — | $655.17M | $416.85M | -$533M | -$825.84M | -$1.96B | -$1.44B | -$1.62B | -$943.59M | -$689.83M | -$91.06M | -$119.16M | -$57.1M | -$18.55M | |
| — | $142.15M | $129.92M | $111.79M | $55.87M | $42.78M | $19.23M | $10.4M | $6.99M | -$15.8M | $2.24M | $54K | $0 | $0 | |
| — | $513.02M | $286.93M | -$644.79M | -$881.71M | -$2B | -$1.46B | -$1.62B | -$948.63M | -$673.77M | -$93.11M | -$119.22M | -$57.1M | -$18.28M | |
| — | — | 5.37% | -16.92% | -35.86% | -141.52% | -123.93% | -526.1% | -221.53% | -339.91% | -39.06% | -11141.78% | -647.71% | -140.22% | |
| — | — | — | — | — | $0 | $0 | -$3.62M | -$1.95M | -$264K | -$194K | $0 | — | -$268K | |
| — | — | — | — | — | — | — | — | — | — | -$93.11M | -$119.22M | -$57.1M | -$18.28M | |
| — | $601.86M | $357.74M | -$694.33M | -$903.74M | -$2.1B | -$1.45B | -$1.61B | -$958.16M | -$672.03M | -$92.64M | -$118.35M | -$59.01M | -$18.49M | |
| USD/shares | — | — | $0.20 | -$0.47 | -$0.65 | -$1.49 | -$1.21 | -$1.50 | -$1.22 | — | — | — | — | — |
| USD/shares | — | — | $0.19 | -$0.47 | -$0.65 | -$1.49 | -$1.21 | -$1.50 | -$1.22 | — | — | — | — | — |
| shares | — | — | 1.42B | 1.37B | 1.36B | 1.34B | 1.21B | 1.09B | 780.7M | 720.75M | 543.19M | 403.62M | 110.6M | 99.86M |
| shares | — | — | 1.47B | 1.37B | 1.36B | 1.34B | 1.21B | 1.09B | 780.7M | 720.75M | 543.19M | 403.62M | 110.6M | 99.86M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
EV/EBIT
—
P/E (TTM)
908.71×
Biotechnology median 7.60×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| United States | $2,880,324,000 | $1,957,498,000 | $1,128,219,000 | $502,626,000 | $495,265,000 | $18,228,000 | $134,689,000 | $42,793,000 |
| China | $1,679,531,000 | $1,411,307,000 | $1,101,951,000 | $840,032,000 | $517,104,000 | $290,646,000 | $221,557,000 | $132,385,000 |
| Europe | $611,369,000 | $362,626,000 | $202,014,000 | $63,257,000 | $163,051,000 | — | — | — |
| All Other Countries Except China United States Of America And Switzerland | $171,809,000 | $78,810,000 | $26,595,000 | — | — | — | — | — |
| All Other Countries Except China And United States Of America | — | — | — | $10,006,000 | $863,000 | $0 | $71,966,000 | $23,042,000 |
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Product | $5,282,061,000 | $3,779,546,000 | $2,189,852,000 | $1,254,612,000 | $633,987,000 | $308,874,000 | $222,596,000 | $130,885,000 |
| Collaboration | $60,972,000 | $30,695,000 | $268,927,000 | $161,309,000 | $542,296,000 | $0 | $0 | $67,335,000 |
| Collaboration Other | — | — | — | — | — | — | $0 | $0 |
| Collaboration Reimbursement Of Research And Development Costs | — | — | — | — | — | — | $27,634,000 | $56,776,000 |
| Collaboration Research and Development Service | — | — | — | — | — | — | $0 | $10,559,000 |
| License Revenue | — | — | — | — | — | — | $0 | — |
| Right to Access Intellectual Property Revenue | — | — | — | — | — | $0 | $0 | — |
| License | — | — | — | — | — | $0 | $0 | — |
Key facts
CIK
1651308
CUSIP
07725L102
13F (30d)
28 filings
8 filers
Visit website
Investor relations